All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment

• Published in: Journal of controlled release Vol. 369; pp. 325 - 334
• Main Authors: Ding, Yuan, Xu, Qianzhu, Chai, Zhilan, Wu, Sunyi, Xu, Weixia, Wang, Jun, Zhou, Jianfen, Luo, Zimiao, Liu, Yu, Xie, Cao, Lu, Linwei, Lu, Weiyue
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2024
• Subjects: All-stage targeted therapy; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Avidin - administration & dosage; Avidin - chemistry; Biotin - administration & dosage; Biotin - chemistry; Blood-Brain Barrier - metabolism; Brain Neoplasms - drug therapy; Cell Line, Tumor; Docetaxel; Docetaxel - administration & dosage; Docetaxel - chemistry; Docetaxel - pharmacokinetics; Drug Delivery Systems; Drug nanocrystals; Erythrocyte Membrane - chemistry; Erythrocyte Membrane - drug effects; Glioma; Glioma - drug therapy; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles - chemistry; Rats, Sprague-Dawley; Red blood cell membrane coating; Red blood cell membrane coating; Glioma; All-stage targeted therapy; Drug nanocrystals; Docetaxel
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2024.03.055

Challenges for glioma treatment with nanomedicines include physio-anatomical barriers (the blood-brain barrier and blood-brain tumor barrier), low drug loading capacity, and limited circulation time. Here, a red blood cell membrane-coated docetaxel drug nanocrystal (pV-RBCm-NC(DTX)), modified with pHA-VAP (pV) for all-stage targeting of glioma, was designed. The NC(DTX) core exhibited a high drug loading capacity but low in vivo stability, and the RBCm coating significantly enhanced the stability and prolonged in vivo circulation. Moreover, the Y-shaped targeting ligand pV was modified by a mild avidin-biotin interaction, which endowed RBCm-NC(DTX) with superior barrier-crossing ability and therapeutic efficacy. The integration of nanocrystal technology, cell membrane coating, and the avidin-biotin insertion method into this active targeting biomimetic formulation represents a promising drug delivery strategy for glioma. [Display omitted]